Pharmacyclics, Inc.  

(Public, NASDAQ:PCYC)   Watch this stock  
Find more results for PCYC
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.92
Shares 77.08M
Beta     -
Inst. own 72%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 2.02% 11.80%
Operating margin 1.84% 16.77%
EBITD margin - 48.35%
Return on average assets 1.52% 9.42%
Return on average equity 1.93% 11.82%
Employees 607 -
CDP Score - -


SUNNYVALE, CA 94085-4521
United States - Map
+1-408-7740330 (Phone)
+1-408-7740340 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.